BioNanomatrix develops nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome. The Philadelphia, Pa.-based company's technology enables identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel, high-throughput format. BioNanomatrix has received several federal product-development grants and is collaborating with a leading global life sciences firm to apply its analytic technology for near-term R&D applications. BioNanomatrix and a partner recently were awarded a major grant to develop a system that can sequence the genome in eight hours at a cost of just $100, which for the first time would make genomic analysis a practical vehicle for a wide range of biomedical and commercial applications. Tracy Warren sits on the Board. (See deal announcement).
Company Web Site